Diagnosis and Prognosis in the “Other” Motor Neuron Diseases
Amyotrophic lateral sclerosis, already a rare condition affecting one to three people in 100,000, nonetheless garners most of the attention in the field of motor neuron disease...
6401 RESULTS
Sort By:
Amyotrophic lateral sclerosis, already a rare condition affecting one to three people in 100,000, nonetheless garners most of the attention in the field of motor neuron disease...
Two of the promises of genetic association studies are better animal models for research and development of therapeutics...
Calculating the risk of impending AD based on levels of CSF Aβ42 has been tricky because the peptide forms insoluble aggregates that muddle estimates of its production rate in the CNS...
Interest in hitting nicotinic acetylcholine receptors for AD treatment is smoldering just below the surface...
A recent population-based study supports the idea that in the oldest old, the relationship between plaques and tangles, and dementia, may be more legend than substance...
This penultimate article in this Alzforum series reports the call of a founding neurogeneticist to reorganize the genetics of Parkinson’s and related diseases...
This news story on the glucocerebrosidase (GBA) gene closes the Alzforum series on emerging concepts in the neurodegenerative disease spectrum...
The mystery of Huntington disease (HD) is how a toxic protein that is expressed in all the cells in the body kills only a select subset of neurons in the brain...
Scientists wrestling the complexities of α-synuclein fluid biochemistry might be forgiven for looking with some envy to a different protein of the neurodegenerative disease spectrum...
Aggregates of TAR DNA-binding Protein-43 are a bad sign in neurons, where they are found in some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD)...
Presenilins deliver the final cut to unleash the Aβ peptides that form the amyloid plaques that gum up the brains of Alzheimer disease patients...
Well over a decade of research into fluid biomarker candidates has reached a point where a so-called “pathological signature” of amyloid-β and tau proteins is beginning to emerge...
Tangible progress in dealing with spectrum diseases will remain limited until the field comes up with more and better biomarkers of their component proteins...
How to protect the proteins in the cell that protect other proteins—the chaperones...
Current work on distinguishing Alzheimer disease from its cousin dementia with Lewy bodies has underscored one intriguing similarity between the two...
No filters selected